Abstract
The article deals with the main problems concerning the optimization of treatment of patients with renal cell carcinoma. Variants of the course of the disease after pseudoprogression are considered. The strategies of differential diagnosis and correction of treatment based on modern ideas about the pathogenesis of renal cell carcinoma are considered in detail. Data of own researches in which the assessment of possibility of treatment without change of preparations in the first and second lines after primary progression is carried out are resulted.
Highlights
В статье рассмотрены основные проблемы, касающиеся оптимизации современных вариантов лекарственного лечения больных диссеминированным почечно-клеточным раком
The article deals with the main problems concerning the optimization of treatment of patients with renal cell carcinoma
The strategies of differential diagnosis and correction of treatment based on modern ideas about the pathogenesis of renal cell carcinoma are considered in detail
Summary
Research Center of Radiology and Surgical Technologies named after academician A.M. Granov, Ministry of Healthcare of the Russian Federation, Saint Petersburg, Russia. For citation: Molchanov OE, Lisitsyn IYu. Pseudoprogression in patients with renal cell carcinoma during immunotherapy. The article deals with the main problems concerning the optimization of treatment of patients with renal cell carcinoma. The strategies of differential diagnosis and correction of treatment based on modern ideas about the pathogenesis of renal cell carcinoma are considered in detail. Почечно-клеточный рак (ПКР) составляет, по данным разных авторов, 2–4 % всех опухолей у взрослых. Средний возраст больных при первичном выявления ПКО составляет 64 года. У 30 % больных при первичном обращении выявляют отдаленные метастазы, а еще у 30 % они развиваются в течение первого года после радикальной операции. В общей популяции больных ПКР пятилетняя выживаемость пациентов с местно-распространенными формами составляет в среднем 67 %, а при наличии отдаленных метастазов — 12 %.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
